CORT — Corcept Therapeutics Incorporated
$72.94
$-0.77 (-1.04%)
Corcept Therapeutics Incorporated, a biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. The company offers Korlym, an oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.
Market Cap
$7.98B
Forward P/E
14.6x
52-Week Range
N/A
CORT Price History
Revenue vs. Net Income
$761M
Revenue · FY2025
Annual. Net margin is shown under each year.
Free Cash Flow
$142M
FCF · FY2025
Annual. FCF margin is shown under each year.
Return on Capital Employed (ROCE)
6.7%
ROCE · FY2025
Annual. Green above 0%, red below. Dashed line marks the 15% compounder threshold.
Total Assets vs. Total Liabilities
4.4x
Assets ÷ liabilities · FY2025
Annual. What the company owns against what it owes. Assets ÷ liabilities is shown under each year.
CapEx as % of Revenue
0.0%
CapEx · FY2025
Annual. Green at or under the 5% maximum target, red above it.
Shares Outstanding
+5.7%
Dilution · FY2025
Annual diluted shares. Under each year: the change on the previous year (green = buyback, amber = dilution).
